<DOC>
	<DOCNO>NCT02841540</DOCNO>
	<brief_summary>This study include Phase 1 dose-finding portion ( Cohorts A B ) four-arm expansion portion . The primary objective study determine maximum tolerate dose ( MTD ) recommend Phase 2 dose ( RP2D ) H3B-8800 administer orally participant Myelodysplastic Syndromes ( MDS ) , Acute Myeloid Leukemia ( AML ) , Chronic Myelomonocytic Leukemia ( CMML ) ass safety tolerability H3B-8800 single agent administer orally daily 5 day on/9 day repeat dose schedule 28-day cycle participant MDS , AML , CMML .</brief_summary>
	<brief_title>Phase 1 Trial Evaluate Safety , Pharmacokinetics Pharmacodynamics Splicing Modulator H3B-8800 Subjects With Myelodysplastic Syndromes , Acute Myeloid Leukemia , Chronic Myelomonocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<criteria>1 . Confirmed diagnosis Myelodysplastic Syndromes ( MDS ) , Chronic Myelomonocytic Leukemia ( CMML ) , Acute Myeloid Leukemia ( AML ) . 2 . The participant must meet follow criterion relevant specific diagnosis : 1 . Participants AML must either refuse consider candidate intensive induction chemotherapy . Previously treat participant evidence persistent recurrent AML peripheral blood and/or bone marrow . Participants must white blood cell ( WBC ) &lt; 15 x 10^9cells/L . 2 . For International Prognostic Staging System ( IPSS ) highrisk intermediate2 MDS , participant must intolerant hypomethylating agent respond 4 treatment cycle decitabine 6 treatment cycle azacitidine , must progress point initiation hypomethylating agent . 3 . For IPSS intermediate1 lowrisk MDS , participant must transfusion dependent red blood cell platelet ( determined instructional practice local standard care ) . Participants red blood cell transfusion dependent must also fail erythropoiesis stimulate agent ( primary resistance relapse response ) serum erythropoietin ( EPO ) level &gt; 500 U/L . 4 . For CMML , participant must treat least one prior therapy ( hydroxyurea hypomethylating agent [ HMA ] ) . 3 . Peripheral Blood Samples : 1 . Cohort A : Screening visit peripheral blood must available retrospective analysis spliceosome mutation interest . 2 . Cohort B Expansion : Screening visit peripheral blood must submit central analysis sponsordesignated laboratory identify spliceosome hotspot mutation SF3B1 , SRSF2 , U2AF1 , mutation ZRSR2 , SRSF2 deletion include amino acid P95 . 4 . Male female , age ≥ 18 year old time consent . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance score 02 . 6 . Adequate baseline organ function : 1 . Serum creatinine ≤ 1.7 mg/dL calculate creatinine clearance ≥ 50 mL/min per Cockcroft Gault formula 2 . Direct bilirubin ≤ 1.5 x upper limit normal ( ULN ) 3. c. Aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) ≤ 3.0 x ULN 4 . Albumin ≥ 2.5 mg/dL 8 . Written informed consent . 1 . Females breastfeed pregnant . 2 . Diagnosis core binding factor leukemia ( ( 8 ; 21 ) , ( 16 ; 16 ) inv ( 16 ) ) . 3 . Participant candidate hematopoietic stem cell transplant time enrollment . 4 . Family history Leber Hereditary Optic Neuropathy , Autosomal Dominant Optic Atrophy , LateOnset Retinal Degeneration , Familial Dysautonomia hereditary mitochondrial disease , unless causative mutation ( ) family determine participant test negative mutation ( ) . 5 . Known prior current retinal optic nerve disease ( eg , Retinitis Pigmentosa , diabetic retinopathy , optic neuritis ) base screen ophthalmology assessment eligibility . 6 . Corrected vision bad 20/40 unless due cataract . 7 . Vitamin B12 , folate vitamin A deficiency . Rescreening follow repletion therapy acceptable . 8 . Use concomitant medication evidence association druginduced mitochondrial optic neuropathy include systemic administration ethambutol , chloramphenicol , linezolid , erythromycin , streptomycin , zidovudine . 9 . Prior exposure cisplatin , 5fluorouracil , tamoxifen , and/or MEK inhibitor within 3 month enrollment and/or ethambutol and/or hydroxychloroquine within 12 month . 10 . Use concomitant medication know strong inhibitor inducer CYP3A4 enzyme unless participant discontinue switch medication . 11 . Received treatment chemotherapy , widefield radiation , anticancer biologic therapy include investigational agent within 14 day study entry . 12 . An active malignancy and/or cancer history least 2 year exception nonmelanoma skin cancer , carcinoma situ , cervical intraepithelial neoplasia , organconfined prostate cancer evidence progressive disease . 13 . Clinically severe cardiovascular disease clinically significant electrocardiogram ( ECG ) abnormality . 14 . Uncontrolled , clinically significant pulmonary disease . 15 . Known active suspected central nervous system ( CNS ) leukemia . 16 . Uncontrolled intercurrent illness . 17 . Known history human immunodeficiency virus ( HIV ) , active Hepatitis B C. 18 . Cardiac troponin ( cTn ) level upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Chronic Myelomonocytic Leukemia</keyword>
	<keyword>H3B-8800</keyword>
</DOC>